Lauren Broom

• Developed and accelerated bit.bio's therapeutic portfolio, managing partnership meetings, conducting diligence and generating road-maps to IND
• Led non-clinical team of 8 direct and indirect reports, driving high performance and execution of critical data packages for partnerships
• Developed and led a therapeutic development program for a neuronal cell therapy for focal epilepsy, facilitating work across translational, cell engineering and process development functions
• Non-Clinical lead for bit.bio's hepatocyte cell therapy for acute liver failure. Pre-clinical representative for MHRA and INTERACT meetings

Non-Clinical Function Lead, Pharmacology

• Pharmacology team lead: Supervised staff and sub-functions across scientific and technical functions and core facilities. Enabled Sana's first INDs (SC291 and SC262), contributing to non-clinical reports and developing data compliance strategy
• Competitive Intelligence partner: Attended ISSCR, ASGCT and ASH yearly and reported back to leadership on trends, organized company-wide presentations on innovation
• Non-Clinical lead for SC451, an iPS derived stem cell treatment for Type 1 diabetes: Led scientific team and kept program on track to IND by performing continuous evaluation of goals, studies and activities, managing timeline and milestones and liasing with clinical manufacturing and controls team for cell production. Represented non-clinical function in regulatory interactions.

Non-clinical function lead, Pharmacology

• Enabled non-clinical workflows at Sana Cambridge site by negotiating and custom-designing Vivarium and building team to manage In Vivo core. Managed pharmacology budget and led communication and evaluation of head count and equipment needs
• Program team member and non-clinical lead for multiple cell therapies and developing platforms: SC295: oncology gene therapy, SC379: glial stem cell therapy, and helped develop the Hypo Immune Platform.

• Research Program Lead for exploratory Neurology Cell Therapy. Portfolio evaluation and indication selection, devised budget and timeline, led team to implement discovery studies.
• Shaped Sana's early Neuro portfolio, leveraging subject matter expertise to conduct diligence for business development opportunities. Engaged with thought leaders and KOLs to guide early program plans

• Developed a novel CNS gene therapies, managing mouse and primate studies. Trained and managed staff, led lab operations, budget, IACUC protocols and tissue bank facility
• Part time 6-month training in patent law at Clark and Elbing, and at Harvard Technology Transfer office

• Developed a novel CNS therapy investigating controlled dopamine replacement from AAV gene delivery in a rat model of Parkinson’s disease